Introduction
The epidermal growth factor receptor constitutes an established tumor target antigen which can be involved in tumorigenesis (1) and which is over-expressed or mutated in many common solid tumor types such as colorectal, head and neck, and lung cancer (2) . Both tyrosine kinase inhibitors and monoclonal antibodies have been successfully developed and approved for clinical applications (3, 4) . The two approved monoclonal antibodies cetuximab (chimeric IgG1) and panitumumab (human IgG2) bind to overlapping epitopes in domain III of EGFR and are similar in Fab-mediated effector functions such as inhibition of ligand binding, tumor growth inhibition and receptor modulation (5) . However, both antibodies differ in their efficacy to recruit effector cells for antibody-dependent cell-mediated cytotoxicity (ADCC): while the IgG1 antibody cetuximab is particularly efficient with NK cells, the IgG2 antibody panitumumab effectively recruits myeloid cells (6) . Interestingly, both antibodies proved to be similarly effective in the treatment of patients with chemotherapy-refractory metastatic colorectal cancer (7) . Furthermore, there is increasing evidence that myeloid cells are important effector cells in cancer and cancer immunotherapy (8) (9) (10) . In vitro, myeloid effector cell engagement is as effective with human IgG2 as with human IgG1 antibodies (6) , but is significantly improved with antibodies of IgA isotypes (11) (12) (13) . Enhanced myeloid cell recruitment by human IgA compared to IgG1 antibodies has been observed against different tumor target antigens such as CEA, CD20, HER-2/neu and EGFR.
However, the immunotherapeutic potential of IgA antibodies has not been explored in humans.
Natural IgA antibodies constitute the dominant isotype in mucosal immunology (14) . By concerting multiple mechanisms of action, IgA antibodies control commensals and prevent the invasion of pathogens, or neutralize those that passed through mucosal barriers (14) .
Important defense mechanisms, such as phagocytosis, oxidative burst, cytokine release and antigen presentation, are mediated by the interaction of IgA antibodies with the myeloid IgA Fc receptor, FcαRI (CD89), which is expressed on monocytes, macrophages, granulocytes, and Kupffer cells (14) (15) (16) . There are important differences in the antibody-FcR interaction between IgA and IgG antibodies (16) : mutagenesis and X-ray crystal structure studies located the FcαRI interaction site to the interface of the Cα2 and Cα3 domains of the Ig α-chain and revealed a bivalent binding mode, while Fcγ receptors bind to IgG at the lower hinge in a 1:1 stoichiometry (16) . Contribution of N-glycans to Fc receptor binding was shown for carbohydrates of FcαRI but was not observed for those of IgA antibodies (17) (18) (19) . This is in contrast to IgG1 where glycosylation of both, FcγRIII and that of the antibody, does influence Author Manuscript Published OnlineFirst on December 3, 2015; DOI: 10.1158/0008-5472. CAN-15-1232 An engineered IgA antibody for cancer immunotherapy. 5 interactions with FcγRIII (20) . Previous studies demonstrated the efficiency of IgA2 antibodies in activating myeloid effector cells for tumor cell lysis in ADCC assays in vitro (11) (12) (13) . Thus, antibodies of IgA isotype may constitute interesting and potent molecules for targeted cancer therapy.
Humans have two genes for IgA heavy chains (HCs) encoding two isotypes -named IgA1 and IgA2 -with three allelic forms of IgA2, described as IgA2m(1), IgA2m (2) and IgA2n (21, 22) . Each of these IgA molecules has distinct structural characteristics. For example, the elongated hinge of IgA1 increases its flexibility thereby possibly allowing binding of more distant epitopes (14) , but the carbohydrates attached at the up to six O-glycosylation sites are difficult to control during recombinant expression (23) and are critically involved in the pathogenesis of IgA nephropathy (24) . This elongated hinge region of IgA1 is not present in human IgA2 allotypes, resulting in a more compact structure (14, 25) . IgA antibodies are stabilized by a variable degree of inter-chain disulphide bridges between both HCs in the Cα2 domain and between HC and light chains (LC) (26, 27) . However, LCs are not covalently connected to HCs in IgA2m (1) , which is the most common allotype in Caucasians. The HCs of both IgA subclasses carry a C-terminal extension of 18 amino acids, called tail piece, which is critically involved in the formation and transcytosis of dimeric and secretory IgA by the polymeric immunoglobulin receptor (pIgR) onto mucosal surfaces (14, 28) . Notably, cysteines 471 and 311 in monomeric IgA are required for covalent linkage to the J-chain and the extracellular domain of the pIgR to form dimeric or secretory IgA, respectively (14) . In contrast to IgG1, IgA antibodies carry a more exposed and heterogeneous N-glycosylation (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) : there are two conserved N-glycans in both IgA isotypes with two and three additional N-glycans for IgA2m (1) and IgA2m(2), respectively. Increasing evidence underlines the impact of glycosylation on pharmacokinetic properties of IgA antibodies (30, 31) . Naturally, IgA antibodies have a significantly shorter serum half-life compared to IgG in men and mice, which is partially explained by the lack of binding to the neonatal Fc receptor (FcRn) (32) .
Additionally, recombinant IgA was previously reported to be rapidly cleared by the asialoglycoprotein receptor (ASGPR), which is predominantly expressed in the liver and clears proteins with exposed terminal galactose (30, 31, 33) . Importantly, the serum half-life of IgG antibodies has been demonstrated to significantly impact on their therapeutic efficacy (34) . Thus, glyco-engineering strategies to increase the serum half-life of IgA antibodies may improve the immunotherapeutic potential of this antibody isotype for clinical applications.
In the present study, we describe the rational design of an engineered IgA antibody directed against EGFR. We removed two N-glycosylation sites (N166 and N337), stabilized heavy and 
Material and Methods:
Experiments with human material were approved by the Ethical Committee of the ChristianAlbrechts-University (Kiel, Germany) in accordance with the Declaration of Helsinki. All experiments in mice were approved by the Animal Ethical Committees of the UMC Utrecht or Christian-Albrechts-Universität in Kiel.
Animals and animal experiments
Immunodeficient SCID mice (CB17/Icr-Prkdcscid/IcrIcoCrl) were used to evaluate the serum half-life in mice (four mice per group). 200 μg of the respective antibody was injected intravenously into the tail vein. Sub-mandibular blood samples were collected daily during treatment, and antibody concentrations were evaluated using human IgA-or IgG-specific ELISA as described earlier (30) . The tumor model with A431-luc2 in SCID mice transgenic and non-transgenic for human FcαRI was performed similarly as previously described (30) .
Experiments with B16F10-luc2-EGFR and BaF3-EGFR cells in C57BL/6 (BL6) and Balb/c mice transgenic (tg) or non-transgenic (nTg) for human FcαRI were performed as described earlier (30) .
For pharmacokinetic imaging antibodies were labeled and separated from free dye using LICOR IRDye 800CW kit (LI-COR, Bad Homburg, Germany) according to manufacturers' protocol. 25 µg of labeled antibodies were injected i.v. into tail veins of 5-6 week old female mice (Athymic Nude-Foxn1nu, purchased from Harlan Laboratories GmbH, Venray, The Netherlands). For injection and imaging mice were anaesthetized with i.p. injections of ketamine (80 mg/kg, Aveco Pharmaceutical, IA, USA) and dorbene (0.5 mg/kg, Pfizer, Berlin, Germany). Ventral views were imaged using a Peltier cooled charged-coupled device camera (NightOWL LB 983, Berthold Technologies, Bad Wildbad, Germany). The excitation source is a ring light used for epi-illumination, mounted 12 cm above the mice. Filters of 740 and 790 nm were used to assess excitation and emission signals, respectively. The exposure time was set to 0.3 sec. Fluorescent signal was quantified as counts per second using Indigo software (Berthold Technologies) with an automated peak search function.
Cell lines
The human epidermoid carcinoma cell line A431 (German Collection of Microorganisms and Cell Cultures (DSMZ), Braunschweig, Germany) and BHK-21 cells co-transfected with FcαRI (CD89) and FcR γ-chain (35) as well as the luciferase transduced A431 cells (30) were cultured in RPMI 1640 containing 10% heat-inactivated FBS, 100 U/ml penicillin and 100 µg/ml streptomycin (media and additives from Life Technologies, Grand Island, USA).
BHK transfectants were positively selected by addition of 1 mg/ml geneticin and 20 µM The human colon carcinoma cell line DiFi and the human glioblastoma cell line A1207 (European Collection of Cell Culture, ECACC, Salisbury, UK) were maintained in Dulbecco´s Modified Eagle Medium (DMEM) supplemented with 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin). A431-luc2, BaF3±EGFR and B16F10-EGFR-luc2 (BaF3 (DSMZ) and B16F10 (American Type Culture Collection, ATCC, Manassas, VA, USA)) cells were kept in RPMI 1640 containing 10% heat-inactivated FBS, 100 U/ml penicillin and 100 µg/ml streptomycin (30) . All cell lines were obtained between 2011 and 2013.
IgA production, purification and characterization
Purified human myeloma IgA2m(1) antibody was used as control IgA2 (Meridian Life Science, Memphis, USA). Monomeric wild type 225-IgA2m(1), named 225-IgA2-wt, and a wild type human IgG1, named 225-IgG1, were produced from the variable regions of the 225 antibody and human constant regions as previously described (13) . The DNA-sequence encoding the mutated IgA2m(1) was generated by Entelechon (Bad Abbach, Germany). The Figure 1 . Further cloning, production, purification as wells as the determination of antibody concentrations, specific production rates, gel electrophoresis, Western blotting as well as the functional characterization were done as described earlier (13, 35) .
Glycoprofiling
The released N-glycans were analyzed as described in detail in a MIRAGE (36) compliant manner in the supplementary material (29, 37) . Relative quantitation was performed using the Quant Analysis tool (Bruker), which determines the area under the curve obtained from the individual extracted ion chromatograms (EIC) from multiple analyses (Supplementary Table   1 ).
Thermal shift assay
Thermal stability was analyzed in thermal shift assay using Sypro Orange (LifeTechnologies). An engineered IgA antibody for cancer immunotherapy. 9 2.5 mg/ml protein and transferred on a white 96-well thin-wall PCR plate and sealed with Optical-Quality Sealing Tape (both Roche, Basel, Switzerland). Plates were heated in a LightCycler 480 (Roche) from 37 to 99°C with a heat-rate of 4°C/sec and 1 min incubation at each degree. Fluorescence was recorded simultaneously using 490 and 575 nm as excitation and emission wavelengths, respectively.
Surface plasmon resonance
Surface plasmon resonance was investigated on a BIAcore T100 system equipped with BIAcore evaluation software V1.2 (both GE Healthcare). Recombinant human soluble FcγRIIIa and FcαRI (both R&D systems) (100 µg/ml) were coated using random amine coupling kit in sodium acetate buffer with pH 4. Binding to soluble FcγRIIIa and FcαRI was measured at 25°C. Sensograms were recorded and kinetics were calculated using a bivalent ligand model.
Cell based assays
Growth inhibition of DiFi cells was analyzed using the 3-(3,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS) assay and performed as described earlier (12) . For the internalization assay, A431 cells were seeded (2.5 
Data processing and statistical analyses and in silico modeling
Data were generated from at least five independent experiments. Graphical and statistical analyses were performed using GraphPad Prism 6.0 (GraphPad Software, San Diego, USA).
Group data are reported as mean ± SEM. Significance was determined by two-way Anova repeated measures test with Bonferroni's post hoc correction. EC50 values were calculated from dose-response curves, reported as means ± SEM and compared by paired Students-t-test to calculate significant differences between data groups. Significance was accepted when pvalues were ≤ 0.05. Heavy chains of IgA2 antibodies were modeled on the basis of the sequence available under the Genbank accession number AY647979 and aligned using I-
TASSER (39).
Research. 
Results

Rational protein design and modeling of IgA heavy chains
Several strategies were combined for engineering an EGFR-directed IgA2m (1) Figure 1C ) (13) . Furthermore, the tail piece was modeled differently for wild type and mutated IgA2 ( Figure 1D ). However, as IgA2.0 contains eight different mutations we may not conclude that the predicted structural changes are the result of one specific mutation.
Production and purification of 225-IgA2.0
Both IgA antibodies were produced in CHO-K1 cells growing serum-free under suspension culture conditions. Single clones stably expressing the antibodies were generated by limiting dilution cloning, and production rates of five 225-IgA2-wt and 225-IgA2.0 producing single clones were evaluated (Figure 2A and B). Significantly higher production rates were detected for 225-IgA2.0 producing clones. Next, antibodies were affinity-purified and subjected to size exclusion chromatography to isolate monomeric IgA2 antibodies. Elution profiles of 225-IgA2-wt preparations displayed a significant amount of polymeric aggregates, whereas the preparations containing 225-IgA2.0 eluted mainly as a single peak ( Figure 2C ). In both cases fractions containing monomeric IgA2 antibodies were pooled and purity of those preparations was assessed by size exclusion chromatography ( Figure 2D ). Thus, higher production rates and lower formation of spontaneous aggregates suggested improved biopharmaceutical properties of IgA2.0 compared to wild type IgA2.
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Biochemical characterization
Molecular mass and purity of monomeric IgA2 antibodies were analyzed by capillary electrophoresis ( Figure 2E ). Under reducing conditions 225-IgA2-wt displayed bands ranging from ~75 to 110 kDa, whereas two distinct bands were detected for 225-IgA2.0 at ~75 and 80 kDa. On native PAGE, monomeric 225-IgA2-wt displayed a single band at the molecular mass of ~160 -180 kDa, whereas monomeric 225-IgA2.0 was detected at a molecular mass of ~150 kDa ( Figure 2F ). Next, affinity purified (using anti-human kappa light chain directed beads) monomeric IgA2 antibodies were separated by gel electrophoresis under denaturing non-reducing and reducing conditions, and silver staining was used for protein detection ( Figure 2G ). Again, the 225-IgA2.0 was detected at a lower molecular mass under reducing (~50 and 60 kDa for HCs) and non-reducing conditions (~150 kDa for monomeric antibody) than 225-IgA2-wt, which dissociates under non-reducing but denaturing conditions in homodimers of LCs (~ 40 kDa) and HCs (~ 100 kDa) as previously described (13) .
Interestingly, polymeric aggregates were detected under non-reducing conditions in the affinity-purified 225-IgA2-wt but not in 225-IgA2.0. Western Blot analyses using peroxidase (POX)-labeled anti-human α-chain specific antibody proved the existence of polymeric aggregates in the affinity purified wild type but not in the IgA2.0 preparations ( Figure 2H ).
Western Blot analyses using κ-chain specific antibody confirmed the covalent linkage of LCs and HCs in 225-IgA2.0 but not in 225-IgA2-wt (Fig. 2I) . Isoelectric focusing was performed using pH 3-10 IEF gels under native conditions to determine micro heterogeneity (Fig. 2J ).
Monomeric 225-IgA2.0 displayed a single band at pH 6, whereas 225-IgA2-wt displayed a remarkable heterogeneity with a pH from 4.5 to 6.5. Next, thermal stability of both wild type and mutated IgA2 was analyzed in a thermal shift assay ( Figure 2K ). Temperature (37-99°C) and fluorimetric shift of Sypro Orange due to protein unfolding was simultaneously measured in a real time PCR cycler. The significantly increased melting temperature of the mutated compared to the wt IgA2 antibody, which is similar to that of 225-IgG1 (Table 1) An engineered IgA antibody for cancer immunotherapy. 13 
Fab-mediated effector mechanisms
Functional characterization of EGFR-directed IgA2 antibodies was assessed by investigating their capability to induce Fab-mediated effector mechanisms. First, both antibodies were compared for binding to EGFR-expressing A431 cells ( Figure 3A) . In these experiments, 225-IgA2-wt and 225-IgA2.0 bound with similar avidity as confirmed by EC50 values (Table 1) .
Next, their ability to block binding of the ligand EGF was investigated by incubating A431 cells with FITC-labeled EGF and increasing concentrations of both IgA2 antibodies ( Figure   3B ). 225-IgA2.0 prevented binding of EGF with similar efficacy as 225-IgA2-wt (for EC50 values see Table 1 ). Growth of EGFR-expressing DiFi colon carcinoma cells was inhibited similarly effective by 225-IgA2.0 and cetuximab, requiring lower concentrations than 225-IgA2-wt ( Figure 3C , EC50 Table 1 ). Internalization of EGFR upon antibody binding was investigated using α-kappa-ETA' ( Figure 3D , Table 1 (Table 1) . Next, the potential of both IgA2 antibodies to mediate ADCC against EGFRpositive A431 cells was investigated in 51 chromium release assays using increasing antibody concentrations and whole blood as a source of effector cells ( Figure 4D ). In these assays, 225-IgA2.0 and 225-IgA2-wt were similarly effective in tumor cell killing, whereas cetuximab was not effective ( 
IgA2-mediated ADCC, whole blood of G-CSF-primed donors was used in ADCC assays ( Figure 4E ). Both EGFR-directed IgA2 antibodies mediated significant lysis of A431 tumor cells and were similarly effective. The contribution of effector cell recruitment in whole blood ADCC assays was investigated by supplementing the FcαRI-specific murine antibody A77.
ADCC mediated by both EGFR-specific IgA2 antibodies was significantly inhibited using increasing concentrations of A77, whereas IgG1-mediated lysis was not affected ( Figure 4F ).
Subsequently, we isolated FcαRI-expressing myeloid effector cells from the blood of healthy donors. In ADCC assays using A431 target cells and PMN (Table 1) and GM-CSF-primed PMN ( Figure 4G ), monomeric 225-IgA2-wt and 225-IgA2.0 triggered similarly effective ADCC. In ADCC assays employing the colon carcinoma cell line DiFi, the glioblastoma cell line A1207, or the oesophageal squamous carcinoma cell line Kyse30 both EGFR-specific IgA2 antibodies were similarly effective. In contrast, cetuximab did not engage granulocytes for ADCC against any of these target cells (Table 1 ). Both IgA2 antibodies were even more effective using GM-CSF primed compared to non-primed PMN, as confirmed by EC50 values (Table 1) . Next, monocytes, which were isolated using CD14-specific magnetic beads ( Figure   4H ), and human monocyte derived macrophages ( Figure 4I ) were analyzed as effector cells in overnight ADCC assays. In these experiments, both 225-IgA2 antibodies were similarly effective in mediating ADCC against A431 target cells by activating monocytes or macrophages for tumor cell killing (Table 1) .
In vivo efficacy and pharmacokinetic properties of EGFR-directed IgA2 antibodies
The efficacy of EGFR-directed antibodies was first evaluated in a syngeneic short-term i.p. Two representative lungs are displayed in Figure 5K . Together, IgA2.0 demonstrated therapeutic activity in three in vivo models against tumor cells expressing different levels of EGFR. Importantly, the engineered IgA antibody was more effective than wt IgA in the long term i.v. but not in the short term i.p. model, suggesting that phamacokinetic differences may contribute to its enhanced activity.
Glycosylation and pharmacokinetic properties of EGFR-directed antibodies
Research. An engineered IgA antibody for cancer immunotherapy. 16 Previous studies indicated that the serum half-life of recombinant IgA antibodies is affected by their glycosylation and by rapid ASGPR-dependent hepatic clearance. Thus, we investigated if the reduced number of N-glycosylation sites of the 225-IgA2.0 lead to an altered global glycosylation profile. For this purpose, wild type and engineered IgA2 were separated on SDS-PAGE, transferred onto PVDF membranes and stained with direct blue 71 (Supplementary Figure 2) . The respective IgA-bands were cut out, N-glycans were enzymatically released using PNGase F, reduced and subsequently analyzed in-depth by PGC nano Liquid Chromatography-ESI MS/MS glycoprofiling ( Figure 6A collected daily during treatment, and serum levels of therapeutic antibodies were evaluated from day 8 to day 16 using human Ig specific Sandwich ELISA ( Figure 6E ). Results demonstrated a sustained higher concentration of 225-IgA2.0 during treatment compared to 225-IgA2-wt in transgenic and in non-transgenic mice ( Figure 6E , Table 1 ). Nevertheless, the serum levels of the respective 225-IgG1 were significantly higher than those of both 225-IgA2-wt and 225-IgA2.0 ( Figure 6E, Table 1 ). However, there was a significant decline in antibody concentrations detectable for 225-IgA2-wt and 225-IgG1, whereas the engineered 225-IgA2.0 demonstrated sustained high serum levels ( Figure 6E , Table 1 
Discussion
Antibody isotypes for tumor immunotherapy
Human IgG1 is by far the most commonly selected antibody isotype in tumor immunotherapy (41) . This decision is based on the well documented activity of human IgG1 to mediate CDC and to activate NK cells and monocytes/macrophages for ADCC (42) as well as its prolonged FcRn-mediated serum half-life (32) . Furthermore, production and purification technologies are well established for human IgG1 antibodies (43) . However, in vitro studies documented that myeloid effector cells -and PMN in particular -were more effective in ADCC by IgA than by IgG1 antibodies (11) (12) (13) . Human IgA antibodies demonstrated significant anti-tumor activity in huFcαRI-transgenic mice, which are required to investigate Fc-mediated effector functions of this antibody isotype in vivo, since mice do not express a functional FcαRI orthologue (30, 44, 45) . However, the serum half-life of recombinant human IgA antibodies in mice was unexpectedly short -probably due to rapid clearance by the ASGPR (30, 31) and the lack of binding to FcRn. This hepatically expressed receptor is known to mediate internalization and degradation of proteins with terminally exposed galactose (33) , which was present on the majority of our previous IgA preparations (30) . These results suggested engineering of an IgA antibody with the aim to improve its pharmacokinetic properties and to evaluate its therapeutic activity.
Engineering of an EGFR-directed IgA2m(1) antibody
Research. When we started to engineer IgA antibodies for tumor immunotherapy, we decided to improve an IgA2m(1) antibody, which is the most common Caucasian IgA2 allotype (22) . The decision to use IgA2 rather than IgA1 is based on a number of reasons: IgA2 lacks the elongated hinge of IgA1, which is associated with potential disadvantages. For example, the IgA1 hinge region is targeted by bacterial proteases and contains difficult to control Oglycans, which are involved in the pathogenesis of IgA nephropathy (14) . Furthermore, IgA2 proved significantly more effective in ADCC than IgA1 and has a prolonged serum half-life compared to IgA1 (11, 30) . First, we introduced a P221R mutation into the Igα heavy chain which enabled a covalent linkage between light and heavy chains (13) . Additionally, this mutation increased the thermal and long-term stability of the antibody. Next, the removal of the free and accessible thiol group in the tail piece further enhanced the stability, as it prevented the formation of dimeric aggregates and potential complexes with other serum proteins (35) . The additional mutations described in this manuscript increased productivity and thermal stability as relevant pharmaceutical properteries. Except for an yet unexplained difference in growth inhibition of DiFi cells ( Figure 3C) , Fab-or Fc-mediated effector functions in vitro were not different between wild type and engineered IgA2 (Figures 3 and   4) . Importantly, however, both molecules differed significantly in their glycosylation patterns.
The glycosylation of IgA antibodies is closely related to their pharmacokinetic properties (30) -suggesting that glyco-engineering strategies may improve their therapeutic efficacy. By comparing sequences and structures of different IgA iso-and allotypes, deletion of the Nglycans at positions 166 and 337 appeared as a rational approach to reduce the overall level of glycosylation, since these sites are not conserved in IgA1. Interestingly, these mutations resulted in an altered global glycosylation profile. It will require further in-depth studies to elucidate whether this effect is caused by minor protein structure alterations making the sites of glycosylation better accessible to the glycan-modifying enzymes of the endoplasmatic reticulum and Golgi network, or whether the oligomannose and less sialylated N-glycans are specific for glycosylation sites Asn166 and Asn337 in the wild type IgA2 protein expressed in CHO cells. Whether these alterations in glycosylation also affected antibody productivity or secretion would require additional studies. Potentially, the reduced number of N-glycans led to an accelerated post-translational processing and thereby enhanced production. However, we cannot exclude that transfection or clone effects (higher gene copy number, gene amplification, genomic loci of insertion) may have altered the production rates of the antibodies. Importantly, our data indicate that the increased terminal sialylation (which masks ASGPR recognized glyco-epitopes) of the engineered 225-IgA2.0 considerably delayed the 19 clearance of IgA antibodies in mice -thereby increasing the otherwise short half-life of recombinant IgA compared to IgG antibodies (30) . Hence, this report further confirms the important role of glycosylation and hepatic clearance by the ASGPR for the pharmacokinetics of IgA antibodies (30, 31) . Although the engineering strategy described above resulted in altered glycosylation and enhanced pharmacokinetic properties of the IgA2.0 antibody, additional improvements appear reasonable. For example, C-terminal fusion of human albumin or FcRn-binding motifs to IgA antibodies, or the construction of IgG/A hybrid antibodies (46) . Also further glyco-engineering strategies or the combination of these novel approaches may further enhance the serum half-life and therapeutic efficacy of IgA antibodies (47) .
Engagement of myeloid effector cells
Myeloid effector cells are considered as important effector cells in cancer and in cancer immunotherapy. Depending on the microenvironment, tumor-associated myeloid cells switch from tumor-promoting to tumor-preventing cells (8) (9) (10) 48, 49) . Thus, myeloid cells constitute a numerous population of powerful effector cells which are present at many tumor sites and which could possibly be recruited by tumor directed antibodies to kill malignant cells (13, 30, 35) . Several studies have previously reported that FcαRI (CD89) is a potent trigger molecule to activate these effector cells in vitro and also in vivo using FcαRI-transgenic mice expressing FcαRI on myeloid cells (11) (12) (13) 30, 35) . Furthermore, especially IgA2 antibodies were strong activators to induce myeloid effector cell-mediated tumor cell lysis, and co-or pre-stimulation with GM-CSF and G-CSF, respectively, could further enhance their efficacy (11) . In this manuscript we describe the development of an engineered IgA2 antibody, which was as effective as wild type IgA2 in engaging myeloid effector cells for ADCC in vitro against cell lines derived from different tumor entities. In a long term xenogeneic model, the engineered 225-IgA2.0 was effective employing FcαRI-transgenic or non-transgenic miceindicating recruitment of both Fc-and Fab-mediated effector functions ( Figure 5D-F) .
However, there was a clear increment in its efficacy if myeloid effector cell engagement via 
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Since there was no difference in Fab-or Fc-mediated effector mechanisms between wild type and engineered IgA2 in vitro, the increased efficacy of the mutated IgA2 compared to wild type IgA2 in the long-term tumor model in vivo could be explained by the sustained higher concentrations during treatment in transgenic as well as non-transgenic mice, whereas wild type IgA2 was rapidly cleared. According to a previous report, where in vivo mechanisms of EGFR-directed antibodies were shown to depend on local antibody concentrations (50), we may argue that the higher serum levels of 225-IgA2.0 compared to wild type IgA2 may constitute more appropriate conditions for the engineered antibody to induce growth inhibition or signaling abrogation in non-transgenic mice and ADCC in FcαRI transgenic mice, respectively. Thus, the prolonged serum half-life of IgA2.0 led to a therapeutic benefit in a long-term, but not in short-term treatment models, in which pharmacokinetic properties apparently did not contribute to therapeutic efficacy. Nevertheless, serum levels of IgG were multiple times higher than those of the respective engineered IgA2 antibody although higher amounts of the latter were applied, while both demonstrated similar in vivo activity under these conditions. Further studies are required to evaluate the relation between the serum half- Antibody preparations purified by anti-human-kappa affinity columns (ahukappa) were exposed to a Superdex200 10x300 size exclusion column to isolate monomeric antibodies. 
